Gralise

Gralise is a brand name for an extended-release formulation of gabapentin, a medication used to treat certain types of neuropathic pain. It is indicated for the management of postherpetic neuralgia in adults. The extended-release design is intended to support once-daily dosing and may offer tolerability advantages over immediate-release forms, though dosing should be guided by a clinician.

Mechanism and use: Gabapentin is a structural analogue of gamma-aminobutyric acid (GABA), but its analgesic effects are not due to direct action on GABA receptors. The drug is thought to modulate excitatory neurotransmitter release by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. Gralise is approved specifically for postherpetic neuralgia and is not approved as a general treatment for seizures.

Pharmacokinetics and administration: Gabapentin is not significantly metabolized by the liver and is excreted unchanged by the kidneys; therefore, renal function influences dosing and adjustments may be required in renal impairment. Gralise is taken by mouth, with or without food, under medical supervision and according to prescribed dosing.

Side effects and precautions: Common adverse effects include dizziness, somnolence, fatigue, and peripheral edema. Other possible effects include ataxia, nausea, and diplopia. Serious concerns may include mood changes, alterations in behavior, suicidality, and hypersensitivity reactions. Caution is advised in the elderly and in individuals with a history of substance use. Potential drug interactions include reduced gabapentin absorption when taken with aluminum- or magnesium-containing antacids and additive central nervous system depressant effects with other sedating medications.

Availability and overview: Gralise is a prescription medicine used within a broader treatment plan that includes monitoring and dose titration. Patients should consult healthcare providers for personalized information on indications, dosing, and safety.